Navigation Links
Arvinas Announces Strategic R&D Collaboration with Merck to Study Novel Protein Degradation Technology
Date:4/7/2015

NEW HAVEN, Conn., April 7, 2015 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

While the specifics of the financial arrangements were not disclosed, Arvinas will receive an up-front payment and funding to support Merck-related research. Additionally, Arvinas could earn up to $434 million if all research, development, regulatory and commercial milestone payments are successfully paid for products against all the targets initially selected by Merck, as well as tiered royalties.

Merck may, at its discretion, elect to expand the collaboration to include additional disease targets. This decision would trigger an additional one-time payment, as well as payment of milestones and royalties on a product-by-product basis. 

"We look forward to working with Merck to create novel drugs to address difficult targets, and we believe this alliance will maximize the value of Arvinas' very exciting and innovative protein degradation technology," said Manuel Litchman, M.D., President and CEO of Arvinas.

PROTACs, or proteolysis-targeting chimeras, are bifunctional small molecules that target proteins for degradation and removal from a cell. These molecules induce a cell's own quality control machinery to bind to a particular protein and "label" it for degradation, thus removing a protein from the system. This contrasts to a more traditional drug development approach that inhibits proteins. However, only 25 percent of the body's 20,000 proteins can be drugged via traditional methods. Proteins that cannot be drugged via traditional methods can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

About Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecule strategies aimed at degrading disease-causing cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients. To address these pathological intracellular proteins, Arvinas is developing a new drug paradigm based on the elimination of these proteins. Our innovative protein degradation technology uses small molecule drugs to "tag" specific proteins to be degraded by the ubiquitin/proteasome system (UPS), which is responsible for the normal turnover of most proteins within the cell.

Based on groundbreaking research conducted at Yale University by our Founder and Chief Scientific Advisor, Craig Crews, Ph.D., Arvinas has developed a platform technology to induce the loss of intracellular proteins: Proteolysis-Targeting Chimera (PROTAC). The ability of PROTAC-based drugs to induce protein degradation (instead of protein inhibition) offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands our ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

Arvinas Media Contact:
Carolyn Hawley
carolyn@canalecomm.com

 


'/>"/>
SOURCE Arvinas
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
2. Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD
3. MabVax Therapeutics Announces Closing of Financing
4. Parata Announces New CEO; Spins off Consumer Health Care Technology Incubator
5. Ohio Based Company Announces a Secondary Option to Affordable Care Act (ACA) for Prescription Drugs
6. Radlink, Inc. Announces Exclusive Sales Agency Agreement with Johnson & Johnson Subsidiary DePuy Synthes Companies
7. Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca
8. PlasmaTech Biopharmaceuticals Announces $5 million private placement
9. Imprimis Pharmaceuticals Announces 2015 Annual Meeting of Stockholders
10. BioLight Announces Strategic Partnership to Significantly Expand Presence in China
11. Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2020)... ... 10, 2020 , ... A device that teaches toddlers to go to sleep ... sleep training system for children, launching today on Kickstarter. Hush Buddy creates and reinforces ... Sleep System, getting a child to sleep soundly is as easy as ready, read, ...
(Date:2/10/2020)... Ky. (PRWEB) , ... February 10, 2020 , ... ... partnership with Healthstat , a leading provider of onsite health clinics. Focused ... SaaS-based population health management software, Healthward ® at its onsite employee health ...
(Date:2/9/2020)... ... , ... Clarence Moses-EL allowed AYBOS to capture his former ... years of wrongful incarceration (Moses-EL was acquitted in 2016). AYBOS Communication Director calls ... in the compounded judicial trauma, destruction of evidence, inhumane treatment and disregard for ...
Breaking Medicine Technology:
(Date:2/16/2020)... ... ... Canadian digital healthcare portal Ask The Doctor has launched a toll-free ... , "It is our duty and it is our responsibility to help people around ... CEO of Ask The Doctor. , Doctors and nurses around the globe are available ...
(Date:2/14/2020)... ... February 14, 2020 , ... The Dr. Oz Show is an ... on health, wellness and medical information. As an upcoming guest on the show, ... be sharing his in-depth medical knowledge. During the segment, Dr. Linkov, a leader and ...
(Date:2/13/2020)... ... February 13, 2020 , ... ... in Northern Virginia: Arlington, Dulles-Aldie, Fair Oaks, Fairfax, Fredericksburg, Leesburg, and Woodbridge, as ... D.C.- and Virginia-based fertility specialists have been named as Top Docs for Infertility ...
(Date:2/11/2020)... ... 11, 2020 , ... The wait is finally over. The first wild card for the 2020 ... has been associating professional sports to a truly special project. , The group was originally ... of athletes with diabetes. They decided to take on the ambitious mission to show that ...
(Date:2/10/2020)... ... February 10, 2020 , ... Buxton is pleased ... healthcare division. In this role, Nikki will support Buxton’s current and prospective clients ... product development. , “The healthcare industry is increasingly understanding the importance of ...
Breaking Medicine News(10 mins):